Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple inhaled gas replace morphine for heart attack pain?

NCT ID NCT07445737

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial will compare methoxyflurane (Penthrox®), a painkiller gas patients inhale themselves, against standard morphine injections for chest pain during a heart attack. About 700 adults with a specific type of heart attack (STEMI) will be enrolled in pre-hospital settings. The goal is to see if methoxyflurane is at least as good as morphine at relieving pain within 30 minutes, with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Methoxyflurane (Penthrox®) inhaled gas
What this could lead to
If it works, this could offer a faster, easier-to-use pain relief option for heart attack patients without needing an IV line.
What could go wrong
This is a non-inferiority trial, so it may only show methoxyflurane is not worse than morphine, not necessarily better. It has not started recruiting yet, and results may not apply to all heart attack patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient age ≥ 18 years * Patient managed in pre-hospital setting for a ST elevation myocardial infarction (STEMI) : Chest pain \< 12 hours with moderate to severe pain (VAS \> 6/10) or STEMI on ECG according to 2017 ESC guidelines Exclusion Criteria: * Previous analgesic treatment for this episode of chest pain * Hypersensitivity to morphine, methoxyflurane, any fluorinated anesthetic or any of the excipients listed in SmPC, * Decompensated respiratory failure (in the absence of artificial ventilation), * Severe hepatocellular insufficiency (with encephalopathy), * Acute head trauma and intracranial hypertension in the absence of controlled ventilation, * Uncontrolled epilepsy, * Treatment with buprenorphine, nalbuphine and pentazocine, naltrexone, nalmefene or sodium oxybate, * Breastfeeding, in case of initiation or continuation after birth of a long-term treatment. * Known malignant hyperthermia or genetic predisposition of the patient. * History of serious adverse effects of the patient or his family after administration of inhaled anesthetics. * History of signs of liver damage after use of methoxyflurane or after anesthesia with a halogenated hydrocarbon. * Clinically significant renal impairment. * Known renal failure with creatinine clearance below 30 ml/min or undergoing extracorporeal renal replacement therapy. * Altered level of consciousness due to any cause, including head trauma, drug or alcohol use. * Clinical evidence of cardiovascular instability (PAS \<90 mm Hg). * Clinical evidence of respiratory depression. * Incapacity to self-assess pain intensity * Incapacity to methoxyflurane self-administration * Known pregnancy, breastfeeding, minors or incapacity (curatorship or guardianship) * Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants * Absence of a Social Security

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stemi - ST elevation myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Avicenne

    Bobigny, 93000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.